A series of systematic reviews focusing on these two drug groups and their effects on ACR in patients living with diabetes concluded that over extended periods, both canagliflozin and empagliflozin decreased ACR by 19–22% compared with control groups, while GLP-1 RA led to a 17–33% reduction in ACR (102). This evidence concerns the gene GCG and diabetes mellitus.